A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target
Andrea Ghelli Luserna di Rorà(Fondazione Pisa), Giorgia Simonetti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Giovanni Martinelli(University of Bologna), Claudio Cerchione(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo)
Cited by 323
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644